Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 820 results for "daiichi sankyo"

DAIICHI SANKYO : Notice on Details of the Share Options
4 Traders

Daiichi Sankyo Concludes Basic Agreement for Transfer of Daiic...

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate Officer, Vice ... Noodls, 1 hour ago
[x]  

116 images for daiichi sankyo

4 Traders, 3 weeks ago
Bio Spectrum Asia, 3 weeks ago
Bio Spectrum Asia, 1 week ago
4 Traders, 1 month ago
Pharma Letter, 2 weeks ago
Drug Discovery and Development, 3 weeks ago
Rediff.com, 1 month ago
Rediff.com, 1 month ago
Scottrade, 3 weeks ago
Lawyers & Settlements, 2 months ago
Livemint.com

Sun Pharma-Ranbaxy deal in CCI crosshairs

Sun Pharma agreed to buy Ranbaxy for $3.2 billion in stock from its Japanese parent Daiichi Sankyo Co. Ltd. It also agreed to take on $800 million of Ranbaxy's debt. Photo: Hemant Mishra/Mint New Delhi: Sun Pharmaceutical Industries Ltd 's ...
 Livemint.com1 day ago Ranbaxy is now Daiichi's  Pune Mirror2 weeks ago Indian bourses' nod for Sun Pharma-Ranbaxy deal  Rediff.com1 week ago Sun Pharma-Ranbaxy deal gets no-objection from BSE, NSE  Hindu Business Line1 week ago
[x]  
Rediff.com

Daiichi files plea to vacate stay on Sun-Ranbaxy merger

Daiichi Sankyo, owner of Ranbaxy Laboratories Limited, has filed a petition in Andhra Pradesh High Court requesting it to vacate the 'status quo' order it issued earlier on Sun Pharma-Ranbaxy merger process.
 Money Control2 months ago Daiichi files plea in HC to vacate stay on Sun-Ranbaxy merger  Business Standard2 months ago Daiichi files plea in HC on Sun-Ranbaxy merger  Times of India2 months ago
[x]  

Daiichi Sankyo and Eli Lilly and Company: Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel

GERRARDS CROSS, England--(BUSINESS WIRE)--Jul. 23, 2014-- Revised guidance from the National Institute for Health and Care Excellence (NICE), recommends once-daily, oral antiplatelet prasugrel (Efient), in combination with aspirin, as a ...
 BusinessWeek1 week ago Cost watchdog expands NHS use of bloodthinner Efient  Big News Network1 week ago Daiichi Sankyo, Inc. And Eli Lilly and Company: Heart Patients In England And Wales Offered More Choice Of Therapies As National Institute for Clinical Excellence (NICE) Extends Recommendations For Prasugrel  BioSpace1 week ago Court Report -- Part II - July 2014 #2  JD Supra16 hours ago
[x]  

Mitsubishi receives approval to manufacture and market diabetes drug

Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd. have announced that Mitsubishi has received approval to manufacture and market the SGLT2 inhibitor, CANAGLU tablets 100mg in Japan, for the treatment of patients with type 2 diabetes ...
 Individual.com2 weeks ago DAIICHI SANKYO -Marketing and Manufacturing Approval in Japan Received for CANAGLU Tablets 100mg  TMC Net3 weeks ago Japan marketing approval for Canaglu; Vaccine license for Daiichi Sankyo  Pharma Letter3 weeks ago Marketing and Manufacturing Approval in Japan Received for CANAGLU® Tablets 100mg  Noodls3 weeks ago
Scottrade

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

USA-based Portola Pharmaceuticals (Nasdaq: PTLA) has entered into a second clinical collaboration agreement with Japanese drug major Daiichi Sankyo (TYO: 4568) to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in Phase ...
 Pharma Letter2 weeks ago Portola, Daiichi Expand Clinical Collaboration  Contract Pharma3 weeks ago Portola inks collaboration deal with Daiichi Sankyo  Seeking Alpha3 weeks ago Portola, Daiichi Sankyo collaborate for Phase III studies of factor Xa inhibitor antidote  Pharmaceutical Business Review3 weeks ago
[x]  

DAIICHI SANKYO -Announcement on obtaining in Japan the marketing and manufacturing license for the 4-valent combination vaccine for the prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis (Polio) 'Squarekids subcutaneous injection syringe'

[July 08, 2014] (ENP Newswire Via Acquire Media NewsEdge) ENP Newswire - 08 July 2014 Release date- 04072014 - Tokyo, Japan - Daiichi Sankyo Co., Ltd. (hereinafter Daiichi Sankyo) and Sanofi K.K. announce that Kitasato Daiichi ...
 TMC Net3 weeks ago DAIICHI SANKYO : Announcement on obtaining in Japan the marketing and manufacturing license for the 4-valent combination vaccine for the prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis (Polio) 'Squarekids subcutaneous injection syringe'  4 Traders3 weeks ago Announcement on obtaining in Japan the marketing and manufacturing license for the 4-valent combination vaccine for the prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis (Polio) Squarekids® subcutaneous injection syringe  Noodls3 weeks ago
[x]  

American Regent's Injectafer® (Ferric Carboxymaltose Injection) Now the Fastest Growing IV Iron in United States

American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a Daiichi Sankyo Group Company), announced today the double-digit sales growth of Injectafer ® (ferric carboxymaltose injection) in 2014, making it the ...
 Town Hall2 weeks ago American Regent Reports Sales Growth of Injectafer  Pharmaceutical & Medical Packaging News1 week ago American Regent's Injectafer (Ferric Carboxymaltose Injection) Now the Fastest Growing IV Iron in United States  Pharmacy Choice2 weeks ago American Regent's Injectafer(r) (Ferric Carboxymaltose Injection) N...  Finwin2 weeks ago
[x]  

DAIICHI SANKYO : New Acinetobacter baumannii Study Findings Recently Were Reported by Researchers at Daiichi Sankyo (Anti-multidrug-resistant Acinetobacter baumannii...

New Acinetobacter baumannii Study Findings Recently Were Reported by Researchers at Daiichi Sankyo (Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection ...) ...
 4 Traders9 hours ago DAIICHI SANKYO : Reports on Hypoglycemia Findings from Daiichi Sankyo Provide New Insights (Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40...  4 Traders3 weeks ago Sanford-Burnham Medical Research Institute  ClinicSpace3 weeks ago

MRC Technology inks collaboration with Daiichi Sankyo

LONDON—MRC Technology and have begun a drug discovery collaboration focused on identifying and selecting novel drug targets that could potentially become potent and selective therapeutics for the treatment of diseases such as oncology, ...
 Drug Discovery News3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less